Long Acting Injectable Medication Study for people with Schizophrenia
Observational Study of LAIs In Schizophrenia (OASIS) (ALKS 9072-A403N)
This study enrolls adults with schizophrenia who are currently in a treatment program for schizophrenia and your clinician is prescribing a Long
Acting Injectable (LAI) medication. The purpose of this study is to learn more about how patients do when they are on these medications.
Your health will be observed over time in order to collect information on the use of atypical Long Acting Injectable (LAI) antipsychotics in people with schizophrenia. We will collect this data about you for about 1 year. Being in the study won't change the usual routine care that you get from your provider. You will still go in for all the regular visits to your provider that you would if you were not in this study. Study takes place at ECMC.
The objectives of this study are:- To describe the demographic, clinical, and socioeconomic characteristics in patients with schizophrenia newly initiated on one of four FDA-approved, atypical Long Acting Injectable (LAI) antipsychotics (ABILIFY MAINTENA, ARISTADA, INVEGA SUSTENNA or RISPERDAL CONSTA).- To describe the treatment patterns in patients with schizophrenia newly initiated on a FDA-approved, atypical LAI over a 12-month follow-up period.- To describe the clinical, economic and patient-reported outcomes in patients with schizophrenia newly initiated on an FDA-approved, atypical LAI over a 12-month follow-up period. Site For OASIS
Adults ages 18+.
Diagnosis of schizophrenia.
Have just started treatment with one of four atypical Long Acting Injectable (LAI) medications (ABILIFY MAINTENA, ARISTADA, INVEGA SUSTENNA or RISPERDAL CONSTA)
Let us know how the study team can reach you.
If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email email@example.com and someone will assist you.